Theriva Biologics, Inc. (TOVX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.21
- As of
Kresmion compiles this page from TOVX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Theriva Biologics, Inc. (TOVX): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
See the full TOVX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TOVX on one page. Preview it with sample data, then open it live with a free account.
Preview the TOVX dossierActive signals for TOVX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 37.3%, EPS $-0.07 vs $-0.051 estimate
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in TOVX
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 64% of TOVX (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 38.9% - EPS $-0.57 vs $-0.9333 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 41.6% - EPS $-0.45 vs $-0.7701 estimate
FREE, NO ACCOUNT
Every signal on TOVX, as it fires
You are seeing 5 of 6 signals recorded on TOVX since 2026-05-26.
The five above landed across 4 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TOVX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 87164U508 · 2026Q2 | $16K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 87164U508 · 2026Q2 | $4K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TOVX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TOVX against its peers
TOVX's return on equity of -154.3% ranks in the 44th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | TOVX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.2M | n/a | 9 |
| Gross margin | n/a | 65.4% | n/a | 5 |
| Operating margin | n/a | -871.8% | n/a | 9 |
| Net margin | n/a | -848.7% | n/a | 10 |
| Return on equity | -154.3% | -124.5% | 44 | 16 |
| 1 year | -52.3% | -60.1% | 63 | 14 |
Peers (22): CALC, ADIL, SNTI, CMMB, JAGX, ZEOX, GTBP, KPRX, MTVA, INTS, BCLI, PHIO, BLRX, OTLC, VTGN, HEPA, GDTC, ASBP, ENSC, BIVI, PLUR, IMRN. Left out: CUBT (no annual filing), MBRX (no annual filing), VICP (period gap). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TOVX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TOVX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TOVX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.